Odiparcil
- Generic Name
- Odiparcil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H16O6S
- CAS Number
- 137215-12-4
- Unique Ingredient Identifier
- FIK1414ZI8
- Indication
Investigated for use/treatment in atrial fibrillation, cardiovascular disorders, thrombosis, and venous thromboembolism.
- Associated Conditions
- -
- Associated Therapies
- -
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT03370653
- Locations
- 🇫🇷
Hôpital Femme-Mère-Enfant, Bron, France
🇬🇧Royal Free Hospital, London, United Kingdom
🇵🇹Centro Hospitalar S. João, Porto, Portugal
Odiparcil QT Definitive Study
Phase 1
Terminated
- Conditions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00437242
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Odiparcil For The Prevention Of Venous Thromboembolism
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 961
- Registration Number
- NCT00244725
- Locations
- 🇬🇧
GSK Investigational Site, Wigan, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath